Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROCIN versus PEDIAMYCIN 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROCIN versus PEDIAMYCIN 400.
ERYTHROCIN vs PEDIAMYCIN 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also exhibits anti-inflammatory and prokinetic effects via motilin receptor agonism.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6 hours.
400 mg orally every 6 hours for 10 days.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in adults; may prolong to 4-6 hours in hepatic impairment or neonates.
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Primarily eliminated via biliary excretion as unchanged drug and metabolites; approximately 2-5% excreted renally as active drug, 15-20% as metabolites; up to 30% excreted in feces.
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic